June 17, 2024

Ebola Vaccine Market Driven By Rise In Ebola Epidemics Globally

Ebola vaccine is a vaccine that is being developed to prevent the deadly Ebola virus disease. The Ebola virus is transmitted to humans from wildlife and spreads in the human population through human-to-human transmission, with the infection causing severe bleeding and organ failure in humans. The vaccine works by inducing the production of antibodies and stimulating the immune system of humans to recognize and fight the virus before getting infected. With Ebola epidemics becoming more common across Africa in recent times, the development of a vaccine is crucial to manage and control future outbreaks.

The global Ebola Vaccine Market is estimated to be valued at Us$ 5.83 Bn in 2023 and is expected to exhibit a CAGR Of 9.4% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:


One of the major trends in the Ebola vaccine market is the development of combination vaccines targeting Ebola and other diseases. Many companies are developing vaccines that can provide protection against Ebola as well as other infectious diseases prevalent in Africa such as malaria, typhoid, measles etc. This is expected to increase the efficacy of vaccination programs conducted in Africa and other developing regions affected by Ebola outbreaks. Combination vaccines help reduce the number of vaccination visits, provide cost benefits, and increase immunization coverage rates of populations living in remote areas with limited healthcare access.


Porter’s Analysis

Threat of new entrants: Low as significant investment is required to develop vaccines coupled with lengthy research and development along with clinical trials.

Bargaining power of buyers: Moderate as government agencies and international organizations are the major buyers of Ebola vaccines.

Bargaining power of suppliers: Low as major players control most of the supply and patents for Ebola vaccines.

Threat of new substitutes: Low as there are no substitutes available for Ebola vaccines yet.

Competitive rivalry: High as major players compete on factors like efficacy, safety, cost and approvals.

Key Takeaways

The Global Ebola Vaccine Market Demand is expected to witness high growth. The market size for 2024 is US$ 5.83 Bn registering a CAGR of 9.4% during the forecast period of 2023 to 2030.

Regional analysis:


North America accounts for the largest share in the Ebola Vaccine market owing to increasing research funding and presence of key players. However, Asia Pacific is expected to witness fastest growth because of growing awareness among populations and rising healthcare investments in countries like China and India.

Key players:


Key players operating in the Ebola Vaccine market are 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode. Major players are focusing on vaccine immunogenicity, effectiveness and supply contracts with global organizations to strengthen their presence.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it